文献速递胸部肿瘤

卡铂、紫杉醇、贝伐珠单抗联合或不联合西妥木单抗治疗晚期非鳞非小细胞肺癌的II期随机试验

Phase II randomized trial of carboplatin, paclitaxel, bevacizumab with or without cixutumumab (IMC-A12) in patients with advanced non-squamous, non-small-cell lung cancer: a trial of the ECOG-ACRIN Cancer Research Group (E3508).
PubMed 文献 · Ann Oncol · 2017-01-01

ECOG-ACRIN E3508研究将175例晚期非鳞非小细胞肺癌患者随机分配至CPB方案(卡铂+紫杉醇+贝伐珠单抗)或CPB联合西妥木单抗组,153例可评估并接受治疗。结果显示联合西妥木单抗未改善无进展生存(中位5.8 vs 7个月,P=0.33)和总生存(16.2 vs 16.1个月,P=0.95),但增加了3/4级中性粒细胞减少、发热性中性粒细胞减少、血小板减少、乏力及高血糖。结论认为该联合方案不推荐进一步开发。

要点

  • CPB联合西妥木单抗未改善PFS(HR 0.92,95%CI 0.65-1.31)或OS(16.2 vs 16.1个月)。
  • 联合组客观缓解率58.7% vs 46.2%(P=0.15),无统计学显著差异。
  • 联合组3/4级中性粒细胞减少、发热性中性粒细胞减少、血小板减少、乏力及高血糖增加。

核心结论

  • 在CPB方案基础上加用西妥木单抗增加毒性而未改善疗效,不推荐在非小细胞肺癌中进一步开发。
  • 两组总生存均长于历史对照,可能归因于多种因素,并强调II期试验中对照臂的价值。

研究设计与样本

  • ECOG-ACRIN癌症研究组开展的II期随机试验(E3508)。
  • 入组贝伐珠单抗适用、IV期或复发非鳞非小细胞肺癌且体能状态良好的患者。
  • 随机分配至CPB方案(紫杉醇+卡铂+贝伐珠单抗,最多6周期后贝伐珠单抗维持直至进展,A组)或CPB联合西妥木单抗6 mg/kg静脉每周一次(B组)。
  • 共175例随机,153例可评估并接受治疗(A组78例,B组75例)。

主要发现

  • 中位无进展生存期A组5.8个月(95%CI 5.4-7.1)vs B组7个月(95%CI 5.7-7.6),P=0.33;风险比0.92(95%CI 0.65-1.31)。
  • 客观缓解率A组46.2% vs B组58.7%(P=0.15)。
  • 中位总生存期A组16.2个月 vs B组16.1个月(P=0.95)。
  • 3/4级中性粒细胞减少和发热性中性粒细胞减少、血小板减少、乏力及高血糖在联合西妥木单抗组增加。

关键数值与推荐

  • 西妥木单抗剂量为6 mg/kg静脉每周一次。
  • 紫杉醇、卡铂和贝伐珠单抗采用标准剂量,最多6周期,后续贝伐珠单抗维持治疗。

临床怎么用

  • 作者结论认为在CPB方案中加入西妥木单抗增加毒性而无疗效改善,不推荐在非小细胞肺癌中进一步开发。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cixutumumab is a fully human IgG1 monoclonal antibody to the insulin-like growth factor type I receptor that can potentially reverse resistance and enhance the efficacy of chemotherapy. METHODS: Bevacizumab-eligible patients with stage IV or recurrent non-squamous, non-small-cell lung cancer and good performance status were randomized to receive standard doses of paclitaxel, carboplatin, and bevacizumab to a maximum of six cycles followed by bevacizumab maintenance (CPB) until progression (arm A) or CPB plus cixutumumab 6 mg/kg i.v. weekly (arm B). RESULTS: Of 175 patients randomized, 153 were eligible and treated (78 in arm A; 75 in arm B). The median progression-free survival was 5.8 months (95% CI 5.4-7.1) in arm A versus 7 months (95% CI 5.7-7.6) in arm B (P = 0.33); hazard ratio 0.92 (95% CI 0.65-1.31). Objective response was 46.2% versus 58.7% in arm A versus arm B (P = 0.15). The median overall survival was 16.2 months in arm A versus 16.1 months in arm B (P = 0.95). Grade 3/4 neutropenia and febrile neutropenia, thrombocytopenia, fatigue, and hyperglycemia were increased with cixutumumab. CONCLUSIONS: The addition of cixutumumab to CPB increased toxicity without improving efficacy and is not recommended for further development in non-small-cell lung cancer. Both treatment groups had longer OS than historical controls which may be attributed to several factors, and emphasizes the value of a comparator arm in phase II trials. CLINICALTRIALS.GOV IDENTIFIER: NCT00955305.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Argiris A, Lee JW, Stevenson J, et al. Phase II randomized trial of carboplatin, paclitaxel, bevacizumab with or without cixutumumab (IMC-A12) in patients with advanced non-squamous, non-small-cell lung cancer: a trial of the ECOG-ACRIN Cancer Research Group (E3508). Ann Oncol. 2017. PMID: 28950351. doi:10.1093/annonc/mdx534

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。